Reddit Posts
Altimmune Stock $ALT to Surge in 2024 - Low market cap and waiting for a buyout
While the FSR and BOWL guys try to pump their flat tires, OMGA up 15% today
Congratulations to those who listened to me on CYTK. Ultra super duper RIP to shorts there. Rolled my profits into OMGA
Upcoming ALT conference, Thoughts?
Upcoming ALT Conference? Thoughts or predictions?
$TWOH Looking good into 2024 and beyond!
Altimmune and Viking are the last two companies left for Pharma to FOMO into the Obesity market
Altimmune and Viking are the last two companies left for Pharma to FOMO into the Obesity market
Who ever told me about ALT…you must be Santa Claus
Stocks on HIGH watch for this week!
ALT has been looking very promising
$ALT to pump massively after partnership announcement
Thoughts on $ALT Altimmune Inc. Gaps gunna fill?
$MGRX #Nasdaq Pioneering the Future of Men's Health
ALT (Altimmune) now primary leader in weight loss prescription
Short squeeze to look early this June a $NVAX $AL $ALT $BYND
Hot Stocks: USX nearly quadruples; ONON jumps on earnings; ALT, AG plunge
You regards are doing bank fds wrong. Do THIS Monday!
Alternus Energy (OSE:$ALT) Announces Business Combination Agreement with Clean Earth Acquisitions Corp. ($CLIN)
Martins ALT zkEnrique didnt even last a week
Why you should buy GOOGL puts and YOLO into Reddit IPO
Biden administration unveils $65 billion plan to combat next pandemics after Covid - Looking at other ‘next pandemic stocks.’ This hit at the closing bell on Friday. Stocks to watch ? SIGA Tech and ALT, what else ?
Biden administration unveils $65 billion plan to combat next pandemics after Covid - Looking at other ‘next pandemic stocks.’ This hit at the closing bell on Friday. Stocks to watch ? $SIGA and $ALT, what else ?
Biden administration unveils $65 billion plan to combat next pandemics after Covid - Looking at other ‘next pandemic stocks.’ This hit at the closing bell on Friday. Stocks to watch ? $SIGA and $ALT popped with decent call volume at close. what else? That’s a serious number for some smaller caps.
Biden seeks $65bn to deal with future pandemics - Covid - Looking at other ‘next pandemic stocks.’ This hit at the closing bell on Friday. Stocks to watch ? $SIGA and $ALT popped with decent call volume at close. what else? That’s a serious number for some smaller caps.
$HUT the most undervalued bitcoin mining company hit NASDAQ today
$HUT the most undervalued bitcoin mining company hit NASDAQ today
ALT SKETCH - RAP BATTLE: DFV vs ELON ROARING KITTY STRIKES FIRST🥊(wait for it)
All aboard: News today, more coming... 🤫🚀
All aboard: News today, more coming... 🤫🚀
Global Tech announces plans to launch an Alternative Trading System similar to Overstock's TZero
Technical Analysis on retarded ALT coin
Let’s go ALT next one to make the climb upwards
ALT ticker little bit of DD and short summary
We are launching a new ALT coin, br0p coin in spring. We will be distributing FREE coins.
ALT is running boys and girls! Come on and let’s push this to $35 by Friday, aye? Just got FDA go-ahead for COVID-19 vaccine, only Ph1 but will go fast. Great potential, mucosal vaccine like VXRT, MYMX, etc.
Mentions
ALT and GUTS serves two different customer base in the weight loss market mate
1. ALT Positive phase=3 Analyst SP=18 https://finance.yahoo.com/news/does-altimmune-alt-potential-rally-145502324.htm 2. There was pull back so gr8 entry n insider purchase. 2026 is FOR ALT.
Or buy ALT with today news of their Drug
ALT at 4.20 now, even better
SLS profit now at 4.70, buy ALT at 4.30 sell at 4.50+ reenter SLS is a play SLS seems to be topping of for now
I spammed here about SLS when it was under $2 (it’s nowhere close to being done) but anyone looking for different plays should look at ALT stock. They have a weight loss drug that is actually better at treating fibrosis. Just got fast track designation for their drug and it’s about 1/10th of the SP that it should be. Buyout will be 5-10b when it comes
ALT might run up close to $5 based off of previous December prices.
ALT Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Hoping ALT can retrace back up to that $5 mark
ALT. BIO on the move imo. Been invested since 2023. Great trend in science and waiting on FDA minutes and release of P3 plan.
Well they better buy ALT because pemivutide is coming for their market share with a better drug.
What makes you think ALT will rebound? It jumped up, then came back to the levels it was about 1.5 months ago. Doesn't seem like a huge drop that warrants definite reversal. I'm genuinely curious as this was a ticker I followed earlier this year
SLS ACET depending on what RS decision is. ALT for the rebound
Bios- ALT is now a penny again and sold on news, probably a good time to buy. ACET is oversold, voting on RS but they have until April for compliance and have stated they want to wait to see if stock price will naturally go up with Q1 updates. SLS is just a great company and that is easy gains.
The market makes absolutely zero fucking sense. Pemvidutide phase 2b trial results come in this morning with huge positive results, and what happens? ALT plummets 20 fucking percent. None of this makes sense
ALT had some positive news for its trial, it spiked a while ago and is currently down 2.5 %.Could be a good price to buy in. Kinda weird that it’s trading lower than its lowest price all month. While I’m writing this it’s already up a bit more so only down about 1% now
Has anyone tried just pressing CTRL+ALT+DEL to reboot the market yet… Or just clearing out its Cache?
Okay. fair comment, since elevated liver enzymes are common with early oral small-molecule trials. But there was only one case of transient elevated liver enzymes in the 1b trial, and they withheld dosing, then reduced the dose and the enzymes normalized and stayed in normal range. And the only other case (of 77 people) was in the 1a trial and it was a mild increase: "One subject had a transient, mild increase in AST and ALT after receiving a single dose of GT-02287". No SAE's.
Sure. As I also said before, I am concerned that the trials have shown that GT-02287 causes elevated liver enzymes (ALT, AST, and alkaline phosphatase). Which, for what would be a long-term medication, could be problematic. But I believe there's also some evidence those levels could normalize over time. So, that feels like a normal biotech risk. I don't like that I've never seen either of you address that in your posts.
$ALT Altimmune should be a top ten trending stock of the week. This is a great summary and highly recommend the read. One thing to make clear is there is no fibrosis readout from biopsy at 48 weeks. That is what could pump the breaks on a massive rally. Also safety and tolerability will be in huge focus and should be stellar based on 24 weeks but needs to be watched still. The 24 weeks data was awesome to those of us who have been in and around MASH data readouts but missed stat sig. I’m surprised the company was so aggressive, even four more weeks may have been just enough to tip the scales since if you think about liver fibrosis improving, that’s literally the liver regrowing and healing parts of itself from a scar. Think about scars from cuts you get. It takes time. Good luck to all! I’m fully loaded.
Thank you, I appreciate the detailed response. If you have time and are interested in an additional play, have a look at Ganx. Like I said, I don't have the skills to assess what's going on with a biotech, but there are several rather detailed dd on these subs, and just like it is the case with ALT, people put a lot of money into it, it's not the usual bots and shills. It's up quite a bit since I entered, same expectation of 2x or more this month. I guess I'm splitting my money between these 2. What calls did you get for ALT? Mine expire on the 19, I might try to roll them if it's too close to the catalyst
Actually looks really decent! [https://biopulse-prod.web.app/analysis?ticker=ALT](https://biopulse-prod.web.app/analysis?ticker=ALT) https://preview.redd.it/tjribk03r86g1.jpeg?width=1320&format=pjpg&auto=webp&s=287027d6e0f50525dd1fdac7357512cd55959cd1
Google "Sam Altman's sister accuses"... how is this guy (with literally zero education... my gardener is more qualified) allowed to be CEO of single-handedly corner the dram market? Feels like "SCAM ALT-MAN" is part of the simulation we live in
$Slno, Sold at 19$ and IT Spikes later to 80$. I bought at 6$ somit was still good. Now with $ALT that will Not Happen again. Believe in what you gold guys
$ALT indiscriminately shorted (23.2M shares) promising biotech is a 2nd gen GLP 1 with improved tolerability, muscle retention and a 2nd mechanism that repairs scarred liver. Huge market and phase 3 coming in '26. 48 wk data any day now. A huge couple weeks here. Green 11 of last 13 days.
ALT is definitely headed much higher!
Great post, ALT is moving higher every day!
Altimmune ALT and ALT, definitely going to 10x-20x!
Lets see about that. [MORE DD](http://aimytrade.io/ticker/ALT)
$ALT surging for the 5th day in a row. Indiscriminately shorted abd they increased the position against Weight loss that retains muscle mass, tolerable, and may be a functional cure for liver disease. Attacks fat. Huge catalyst upcoming. This baby will fly 22.3$ shorted now
Yes, you do! ALT has gained roughly 50% in the last ~3 months. It is headed much higher and will likely be at the center of a bidding war with big Pharma. Look at what just happened between Pfizer and Novo over Metsera, which has a substantially inferior drug compared to Altimmune. Metsera ended up going to Pfizer in a $10 billion buyout. ALT is gold!
ALT will rocket in the near future!
$ALT massive call options coming in. $35k on 5.5 strike dec 5. Dec 19 and Jan 16 they go up to 20$ . Huge catalysts against indiscriminate shorting. Sign me up
ALT GUYS… pay attn i bought 10k at 4.97 yesterday it’s at 5.16 was at 5.24 has a strong buy and a good price projection
$ALT high short interest (21%) surge continues. MM will try to push it down early for discounted shares. High quality weight loss with best in class credentials for liver disease. Weight loss with a new liver. Indiscriminately shorted by GS & Kerrisdale. See you on the moon.
Indiscriminately shorting into a surging biotech.$ALT shares on the move with great tolerability, saves muscles, and targets fat especially in the liver! Big catalyst soon. Maybe buyout. These guys offered up another 980 shares sub $5. Go get em
ALT up over 6% today and headed much higher!
Same. I've been in ALT for about a year or more Sold most of my position with the last big drop. But I've been slowly buying shares and options when I can Hoping the Q4 news gets us well into the double digits
I dont pump NFE. ALT is a possible buyout. Please go get checked, you are in way too deep emotionally.
Any idea what ALT's cap is
ALT is a long term investment, but glad to see it's gaining some attention now as I'm invested in this 😚
So pick up DNUT and ALT - either GLP-1 or diabetes will take off - either way your betting on Americans being unhealthy, pretty safe play! Plus Krispy just announced a line of Peanuts (picture Snoopy) products, who doesn’t love Snoopy!
Altimmune $ALT is one of the next upcoming tenbaggers!
$ALT scooping up sub $5 this morning. The hottest next Gen glp1 about to enter phase 3. Demand is white hot. & it heals your liver !
Send Altimmune $ALT to the moon!
Great post! Altimmune is incredibly undervalued and currently on a steep upward trajectory with many catalysts on the way. The company is currently setting at a 500 million market capitalization and should be at a a market capitalization of 4-5 billion. This is hands down the best value in biotech at the moment. I’m currently acquiring as much of this stock as I can as fast as possible! Thanks for posting, ALT is truly a rocket ship that is getting ready to take off!
Altimmune $ALT, buying as much as possible before it rockets higher!
Altimmune (ALT), buying as much as I can!
$ALT is so undervalued and a prime target for a buyout! I’m loading fast!
$ALT trending as a buyout target of $SNY on ST all wknd. 21% short interest, good momentum. Broke $5 Sunday night. Numerous high impact catalyst upcoming up & indiscriminate shorting of promising biotech about to bite shorts in the bottom on this one.
You bring up a great point about transparency... Pemvidutide/ALT Phase 2 data was just published in The Lancet 2 weeks ago. You don't get any better than this - I heard their supplement for peer review was nearly 180 pages long (typically it's under 10 pages for others). Transparency on steriods. People are still waiting for a peer like Viking to publish their phase 2 results (big flag to many) something that ALT has already done. Can't wait for 48-week data to drop any minute now.
I always feel like the perma-bear on this Sub but comparing ALT directly to peers acquired for billions appears premature absent clear, peer-reviewed 48-week data showing superior clinical benefit or a strategic partnership. I have mentioned this before but I invested in bio tech and got *burned*
"but it's the ALT season"
ONDS, ACHR, and ALT calls are my move
Beg, borrow or steal as many shares of $ALT as you can. Don't say I didn't warn you.
$ALT check out this high quality weight loss & liver fat reduction molecule. Price suppressed for a long while. 48wk data is due and partnership or buyout VERY likely. The stock broke out today for the first time potentially signaling a transaction or data soon! A very valuable molecule at the right time. All aboard!
$ALT on sale - but not for long....
Am I able to CTRL+ALT+DLT my port pls
Options on Jan 16 for ALT are selling at strikes up to 5X the current price!
Don’t worry boys ALT SZN around the corner!
Altimmune/Pemvidutide has the potential to be the Best-in-class for MASH. I wouldn't be surprised if NVO is turning to ALT/Pemvi for their next acquisition/target after loosing an inferior drug to Pfizer (Metsera) for $10B. Doctors are saying if Pemvi were approved now - they'd be putting a ton of patients on it - "one dose, no titration, well tolerated. MASH resolution on autopilot" as one Doctor put it. This is by far the most undervalued company in bio.
Tomorrow morning buy $ALT Altimmune. Any positive data tomorrow at the latest breaking presentation, the stock will be $20. This is the biggest opportunity for tomorrow
ALT. All eyes on the late breaking oral podium presentation tomororw 1145am at AASLD. A next generation GLP with unique 1 to 1 glucagon ratio. The biggest TAM in the world and this one targets fat specifically in record time. Works in 12 wks & stat significance in 24 weeks for fibrosis & weight loss. Better quality WL than good diet and exercise. 21% lean mass preservation vs 24% good diet/exercise The cat is out of the bag on how good this drug is now. Treats the full spectrum of liver diseases, with quality weight loss in record time. Huge markeatable advantage. Unveils tomorrow its going to be a wild Christmas rally after GS suppressed the price all year.
ALT 25% short. Fat targeted weight loss that reverses liver fibrosis (new liver). New data best in class potency in half the time (24wks) and GS has suppressed the price for months creating opportunity. Podium oral presentation tuesday at AASDL. High tolerability, speed and ease of use are huge advantages. Bidding war soon & pfizer just paid 10B for a phase 1. 360M marketcap is going to rip very soon. Going into phase 3 should be worth MUCH MUCH more. Boards are abuzzing!
A phase 1 obesity asset. ALT is about to say hold my beer. Lean mass preservation, fast acting, great tolerability. Lose your fatty liver with a side of weight loss. About to be huge with a podium presentation Tuesday 11am at AASLD. Front and center. Go time.
Sometimes I forget about all the NSFW subs I was a part of when I first made this account and then I scroll over and am reminded of the filth I was once a part of! CTRL+ALT+DLT my past pls!
ALT man save stock market, more at 11
Bitcoin about to go below $100K for the first time in six months. The dollar index has been rising, so with a strong dollar, all your ALT stores of value will do shite in a shitty sandwich. If the dollar dumped down to 2008 levels, you regards would be millionaires. God luck with that. https://www.marketwatch.com/investing/index/dxy
Bitcoin about to go below $100K for the first time in six months. The dollar index has been rising, so with a strong dollar, all your ALT stores of value will do shite in a shitty sandwich. https://www.marketwatch.com/investing/index/dxy
MUH TOM LEE MUH ETH GOING TO 6K ALT COIN SZN!!!! Hey guys, maybe, just maybe, that ship sailed and you aren’t striking lightning in a bottle twice? Who the fuck are all of you to call a 4-year cycle on make believe magical computer coins anyway? Maybe the market has moved on to things that actually matter like companies generating profit? MUH MAGICAL COMPUTER COINS!!!
$ALT looks primed for a breakout soon. Business update Nov 6. Late Breaking data poster Nov7 & oral presentation Nov11 @ AASLD nov 8-11. Obesity phase 3 ready. MASH resolution & fibrosis improvement best in class at 24 weeks once FDA accepts NITs any day. 48wk top line NITs & end of phase 2 FDA meeting minutes also anyday! Renewed bidding wars between pfizer and Novo for a phase 1 obesity asset the same day Lilly announced their glp1 is the best selling drug in the world. GS has been suppressing this SP indiscriminately to protect the market for their customers NOVO & LILly. A huge risk reward value only days away from business updates AND key oral presentation at THE liver conference of the year. Now is the time to load up! The price has been pinned for months abd the short interest is 25.5%. This drug pemvutide is next generation. Better quality weight loss than good diet and exercise(21% lean muscle loss vs 24% typical diet & exercise), great tolerability due to proprietary euport technology, 74 % liver fat reduction. 6% weight loss at 24 weeks. Its a healthy new liver for all drinkers with a side of weight loss. The next generation GLP1 at $4. Your damn right im holding! Who doesn't love an underdog story right before their breakout
Appreciate that my man. The more you dig on ALT the more confident you get with this could have some serious movement starting this month. My money is on up ⬆️
But something you can HODL for weeks and months Move to ALT5 sigma $ALTS
This won’t age well Move to ALT5 sigma $ALTS
Regarding GLP-1s, have you seen anything about Pemvidutide from ALT? Supposed to treat liver disease and maybe alcohol use disorder. I saw somewhere the results weren't beyond the placebo group and that's why the stock is low. But I read an article that made the drug sound pretty effective at reducing liver fat and even fibrosis. Just curious
ALT (Altimmune), the most undervalued stock in all of biotech!
if you want to fuck goldman in the ass for protecting the glp1 franchises and barring new entrants, slap them in the forehead with a big $ALT 'sroom. they've been suppressing $ALT for over a year, knowing it's the next iteration of glp1s. 25% short interest, bidding wars right now for obesity/mash drugs. punish them for their foolishness.
$ALT is being manipulated by GS to protect NVO and LLY...but data are better. 25% SI. This could run hard when buyout rumors start, bidding wars in MASH/obesity drugs and a paucity of p3-ready options.
Hey all, Not a buy/sell call — sharing a setup I’m watching because the risk/reward is changing with time-boxed catalysts and shorts are still in. 1. Structure first: why this even matters • Ticker: $ALT • Float: relatively tight vs. daily volume on news days • Shorts: still meaningful — which = fuel if they’re wrong on timing • Catalyst window: company already put dates in the public domain (earnings + liver data), so we actually know when the next info hits • Sector narrative: obesity/MASH names are back in rotation — attention helps. When you get (shorts) + (attention sector) + (dated catalyst) you don’t need everyone to pile in — you just need enough volume ahead of the date to make shorts uncomfortable. 2. What the crowd is likely to react to • It’s a data/name stock, not a zombie shell. • The drug (pemvidutide) has real 24-week data in MASH/weight already out there. • Management already said they’re moving toward 48-week data + FDA conversation. That’s a story people understand: “data → talk to FDA → Phase 3”. • That’s easy for Reddit/FinTwit to narrate. So you’ve got a story people can repeat in 1–2 sentences — that’s underrated. 3. Why shorts stay in (and why that’s a tell) Shorts love these because: 1. It’s biotech (binary outcomes, dilution risk). 2. Phase 3 in MASH is expensive → “they’ll raise”. 3. Data not 100% de-risked → “I can stay short until the readout”. That’s fine — but when the calendar gets close and volume wakes up, shorts have to rethink sizing. That rethink = potential upside pressure. 4. What to watch (this is the important part) • Volume spike before the event – if average daily volume suddenly 2–3x’s without bad news, someone is positioning. • Option chain getting busy – especially if OTM calls pick up in the same expiry as the catalyst. • Tape around pre-market/last hour – if it keeps getting bought back after dips, that’s someone absorbing. • Company IR drops slides/posters – gives fresh material for socials to circulate. If 2 or more of those happen at the same time, shorts don’t have a free ride anymore. 5. Possible headlines the market can latch onto This is how I expect people to talk about it (this is psychology): • “Small float MASH name with real data coming” • “Shorts still in before the 48-week readout” • “Next GLP-1/MASH sympathy runner?” • “Call today – management will have to guide” You don’t need them to be true in the strongest sense — you just need them to be plausible based on public info. 6. Risks (read these, seriously) • If the company pushes the timeline → setup weakens. • If they guide to a big, near-term raise → shorts relax. • If the 48-week data underwhelms → it unwinds fast (biotech). • This is not BYND — that was a perfect storm of short interest, meme ETF flows, and viral clips. Don’t assume repeat.
Altimmune ($ALT) — Near-term catalysts in MASH; 48-week readout and FDA meeting on deck Altimmune’s dual GLP-1/glucagon agonist pemvidutide has positive 24-week Phase 2b data in MASH with weight loss and strong NIT signals. Near-term catalysts include: (1) Q3 results + business update on 6 Nov 2025, (2) AASLD late-breaking oral/poster the same week, and (3) 48-week IMPACT data in Q4 2025, followed by an End-of-Phase-2 (EOP2) FDA meeting targeted for Q4 2025. Cash was $183.1m (30 Jun 2025). Watch short-interest dynamics and the Phase 3 path in MASH. Investment thesis (biotech-focused, medium risk) Clinical signal: At 24 weeks, pemvidutide met the primary endpoint (MASH resolution without fibrosis worsening) with up to 59.1% response in ITT analysis, alongside meaningful weight loss and improvements on NITs (e.g., ELF, VCTE, cT1). These markers support anti-inflammatory and anti-fibrotic activity pending biopsy-based confirmation at 48 weeks. What’s different: Company secured late-breaking slots at AASLD 2025 (oral + poster) for 24-week data, a credibility signal in liver circles, and guides to 48-week IMPACT data in Q4 2025 (weight, NITs, safety). Execution adds up: Altimmune scheduled Q3 results and business update on 6 Nov 2025; management recently strengthened clinical leadership by appointing Christophe Arbet-Engels, M.D., PhD as CMO to steer Phase 3 in MASH. Near-term catalysts (dated) 6 Nov 2025 (Thu): Q3 results & business update call (watch for Phase 3 colour, 48-week timing, cash runway commentary). 7–11 Nov 2025: AASLD The Liver Meeting late-breaking oral + poster on 24-week IMPACT data; expect slides/posters on the IR site. Q4 2025: 48-week IMPACT readout (weight loss trajectory, NITs, safety; biopsy subset/AI fibrosis analyses may be discussed). Company also targets EOP2 FDA meeting in Q4 2025 to align Phase 3. Balance sheet & ownership watch-outs Cash: $183.1m as of 30 June 2025; net loss $22.1m for Q2. Provides a cushion into 2026, but Phase 3 will be capital-intensive—monitor financing overhang. Short interest: As of 15 Oct 2025, reported short interest around 21.5m shares (down vs end-Sept). Any data surprise can move borrow/price quickly. Pipeline context (beyond MASH) Obesity: EOP2 meeting for obesity completed previously; programme remains a strategic option post-MASH clarity. Adjacencies (liver/behavioural): RECLAIM (AUD) and RESTORE (ALD) Phase 2 trials initiated in 2025 - optionality if MASH succeeds. Key risks Biopsy-level uncertainty: 24-week signals are strong, but regulators care about biopsy endpoints and longer-term safety; 48-week data are the inflection. Funding/dilution: Advancing to MASH Phase 3 likely requires more capital. Watch the Q3 call and subsequent filings. Competitive landscape: GLP-1s and emerging MASH agents are crowded fields; differentiation on efficacy/tolerability, fibrosis impact, and combo potential will matter (AASLD discussion will help).
$ALT looks primed for a breakout soon. Late Breaking data & oral presentation @ AASLD nov 8-11. Obesity phase 3 ready. MASH resolution & fibrosis improvement best in class at 24 weeks once FDA accepts NITs any day. Renewed bidding wars between pfizer and Novo for a phase 1 obesity asset the same day Lilly announces their glp1 is the best selling drug in the world. GS has been suppressing this SP indiscriminately to protect the market for their customers NOVO & LILly. A huge risk reward value only days away from business updates AND key oral presentation at THE liver conference of the year. Now is the time to load up! This drug pemvutide is next generation. Better quality weight loss than good diet and we exercise(21% lean muscle loss vs 24% good diet & Exercise), great tolerability due to proprietary euport technology, 74 % liver fat reduction. 6% weight loss at 24 weeks. Its a healthy new liver for all drinkers with a side of weight loss.
I’m looking for guidance on my next investment moves based on the portfolio below. My plan is to build a stock portfolio and invest aggressively every month, while continuing to accumulate gold, silver, and crypto (BTC/ETH). Do you agree with this approach or recommend adjustments? 40M USA Self-Employed/Employed Consultant Bank: \~450K Consulting Company: \~48K/month (Expenses: $3K/month) Consulting Jobs: \~315K/yr (Contracts) House: \~2M (Paid Off) Crypto: \~490K (70% BTC/20% ETH/10% ALT Coin Garbage) Gold/Silver (Physical): \~375K Stocks: \~23K Debt: None
INHERITED IRA NON SPOUSE BENEFICIARY I recently inherited $80K as a non spouse beneficiary from Wells Fargo account, now called WellsTrade IRA and it’s labeled a cash/cash ALT. I know I must deplete it in 10 years and I plan to take the minimum each year. Hearing conflicting rules. Can I roll whole amount into my own IRA without taxes and have tax free investing? Or is my only option to invest and withdraw the RMDs and be taxed accordingly? If this is the case I would invest in something with high yield over 10 years. Any sound financial suggestions appreciated.
ALT (Altimmune) has a superior drug candidate and is a much better investment, hands down!
ALT is set up for 3x in next two months
I really do t know why they don’t just buy their win glp1 drug that’s in late development and get it across the finish line. They can buy ALT for what is essentially chump change compared to the market they need to be in for this. ALT’s drug is a pretty good bet to be approved but they don’t really have money - seems like a company like hims could make this all work.
Well, good luck to you too. I’ve got my own picks for this month: $HUMA, $PASG, $JSPR, and $ALT Not financial advice — if you’ve got complaints, you can shove them where the sun don’t shine. Still, you might wanna check these out
the trade this year was ALT AI's - basically like a crypto alt season. Anything that was AI related that wasn't nvidia did insanely well. MU, AMD, ORCL, SNDK, etc, etc. Nvidia only pumped \~40%, the ats pumped 150%+
CTRL ALT DELETE, market resets back to new ATH